<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04956146</url>
  </required_header>
  <id_info>
    <org_study_id>HMPL-013-FLAG-L101</org_study_id>
    <nct_id>NCT04956146</nct_id>
  </id_info>
  <brief_title>Fruquintinib Combined With Sintilimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Single Arm,Open-label, Phase II Study of Fruquintinib Combined With Sintilimab and Chemotherapy in Patients With Unresectable or Metastatic Advanced Wild-type Genotype Non-squamous Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II study to assess the efficacy and safety of Fruquintinib Combined With Sintilimab&#xD;
      and Chemotherapy as a first-line treatment in patients with unresectable or metastatic&#xD;
      advanced Wild-type Genotype non-squamous Non-small Cell Lung Cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>To assess the efficacy of Fruquintinib Combined With Chemotherapy as second-</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>CR + PR rate according to the RECIST version 1.1 guidelines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>CR + PR + SD rate according to the RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival（OS）</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Overall survival is determined from the date of treatment to death from any cause or the last follow-up date</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Fruquintinib Combined With Sintilimab and Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fruquintinib，Sintilimab，Pemetrexed，Carboplatin</intervention_name>
    <description>Fruquintinib,fruquintinib at the dose determined in phase safety lead-in,5mg-intermittent (2 weeks on/ 1 week off) ，po，every 3 weeks(q3w) ; Sintilimab at the dose 200mg，iv, d1, given every 3 weeks (q3w); Pemetrexed at the dose 500 mg/m2，iv，d1，given every 3 weeks (q3w); Carboplatin at the dose AUC=4~5，iv，d1；given every 3 weeks (q3w); Maintenance treatment：After 4~6 cycles of carboplatin treatment, Sintilimab 200mg, iv, d1, q3w；Fruquintinib RP2D intermittent(2 weeks on/1 weeks off), po，q3w； pemetrexed 500mg/m2, d1,iv, q3w until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal</description>
    <arm_group_label>Fruquintinib Combined With Sintilimab and Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntary provision of informed consent.&#xD;
&#xD;
          2. Males or females aged 18-75.&#xD;
&#xD;
          3. Histological or cytologically confirmed NSCLC, metastatic or non-resectable (stage&#xD;
             IIIB-Ⅳ).&#xD;
&#xD;
          4. Not suitable for targeted therapy (patients with non-squamous NSCLC have no EGFR, ALK,&#xD;
             gene mutation)&#xD;
&#xD;
          5. At least one lesion can be measured by imaging.&#xD;
&#xD;
          6. Have not received systemic treatment in the past.&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1.&#xD;
&#xD;
          8. Life expectancy ≥ 12 weeks.&#xD;
&#xD;
          9. Female of childbearing age must have a negative pregnancy test (serum or urine) within&#xD;
             7 days before enrolment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Histological or cytologically confirmed small cell lung cancer (SCLC), including lung&#xD;
             cancer mixed with SCLC and NSCLC.&#xD;
&#xD;
          2. Diagnosed with other malignant diseases other than NSCLC within 5 years.&#xD;
&#xD;
          3. Have participated in other interventional clinical research treatments now or within 4&#xD;
             weeks.&#xD;
&#xD;
          4. Have previously received multi-targeted kinase inhibitors therapy.&#xD;
&#xD;
          5. Have active autoimmune diseases requiring systemic treatment within 2 years.&#xD;
&#xD;
          6. Received systemic glucocorticoid therapy or immunosuppressive therapy within 2 weeks.&#xD;
&#xD;
          7. Clinically uncontrollable pleural effusion/abdominal effusion.&#xD;
&#xD;
          8. Vaccinated vaccines or attenuated vaccines within 4 weeks before the group;&#xD;
&#xD;
          9. Pregnant or breastfeeding females.&#xD;
&#xD;
         10. Other serious hazards to the safety of patients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yongqian Shu, PhD</last_name>
    <phone>00862568306428</phone>
    <email>shuyongqian@csco.org.cn</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 30, 2021</study_first_submitted>
  <study_first_submitted_qc>June 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

